Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by SPCEO1on Mar 02, 2022 1:28pm
168 Views
Post# 34475712

RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructive

RE:RE:RE:RE:RE:RE:RE:RE:Very difficult to be constructiveI am personally not ready to move in that direction yet. But I am open to any ideas anyone might have. We probably have enough shareholders to cause a fuss if we wanted to but I am not sure we have enough to vote anyone off the board. Even had I voted my shares against board members last year, they would not have lost their seats. There is at least one other key shareholder who would need to join and, since SP controls fewer shares this year, you might need even more to effect any real change. Obviously, the timing is hard too as we should be hearing about the phase 1a results right around the time of the AGM. If there are good results, it will likely be hard to muster enough "no" votes to make any changes. If the results are bad, it may be too late to take any action. So, I am not seeing an easy path to make changes but messages can still be sent with your vote. They may not be received, but they can be sent.

Scioto1 wrote:
Wino, SPCEO, others, what are your assessments? Do we have like minds to craft a simple and measurable agenda? How do we use the meeting and board elections to advance a stockholder value agenda?


<< Previous
Bullboard Posts
Next >>